Home

BMS-833923 (XL139)

BMS-833923 (XL139) is a small molecule inhibitor of Smoothened (SMO), a component of the hedgehog (Hh) signaling pathway. Exelixis discovered BMS-833923 and out-licensed the compound to Bristol-Myers Squibb Company. BMS-833923 is currently being characterized in a Phase 1b clinical trial in combination with dasatinib in CML patients.

  • About Us
    • Management
    • Board of Directors
    • Collaborations
    • Locations
    • Contact Us
  • COMETRIQ™
  • Pipeline
    • GDC-0973 (XL518)
    • Partnered Compounds
  • Clinical Trials
    • Exelixis Clinical Trials
    • National Cancer Institute Sponsored Trials
    • Investigator Sponsored Trials
    • FAQs about Clinical Trials
  • Medical Information
  • Investors & Media
    • Management and Board
    • Corporate Governance
    • Stock Information
    • Analyst Coverage
    • Earnings Estimates
    • Earnings Ratings
    • Annual Reports
    • SEC Filings
    • Press Releases
    • Event Calendar
    • Media Resources
    • Information Request
    • Investor FAQs
    • Contact IR
  • Careers
    • Job Opportunities

Pipeline

  • GDC-0973 (XL518)
  • Partnered Compounds
    • Foretinib (GSK1363089, XL880)
    • SAR245408 (XL147)
    • CS-3150 (XL550)
    • SAR245409 (XL765)
    • BMS852927 (XL041)
    • BMS-833923 (XL139)
    • PI3K-δ (XL499) Inhibitor Program
    • TGR5 (XL475) Agonist Program
    • ROR Antagonists
© Exelixis, Inc. 2013   Website design: Hane Chow, Inc.
  • Privacy
  • Terms of Use